Financial News
Parexel Named “Best Contract Research Organization” at 19th Annual Scrip Awards
DURHAM, N.C., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Parexel, one of the world’s largest clinical research organizations (CROs) providing the full range of Phase I to IV clinical development services, today announced today announced it has been named “Best Contract Research Organization” in the Full-Service Provider category at the 19th Annual Scrip Awards. The Best CRO ranking from Scrip follows the company’s recognition earlier in the year as Top CRO to Work With in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey and winner of the 2023 Society for Clinical Research Sites (SCRS) Eagle Award recognizing the CRO committed to advancing the clinical research profession through strong site partnerships.
“Parexel colleagues are passionate about developing life-changing new therapies to advance world health,” said Chief Executive Officer Jamie Macdonald. “This exciting recognition is a true testament to their efforts and collaboration with our customers, sites and partners across the clinical research enterprise to make a difference for patients. We remain committed to innovating across Phase I to IV clinical development to drive research forward and make clinical trial participation more accessible and inclusive for all.”
The annual Scrip Awards, organized by Citeline, the leading provider of drug, device, company, clinical trial and market intelligence in the pharmaceutical and medtech markets, are designed to celebrate and recognize the very best innovations and achievements in global biopharma. Winners were named across 14 categories, including Best Contract Research Organization, which recognizes the critical role CROs play in the drug development process. Parexel was selected by a distinguished panel of life science industry executives based on the company’s capabilities and strengths in delivering results to exceed sponsor expectations; innovations in patient engagement and recruitment; commitment to diversity and inclusion in clinical trials and ability to leverage AI and RWE to evolve the clinical development process to better serve patients. Parexel was recognized at the Scrip Awards ceremony Nov. 16 in London.
About Parexel
Parexel is among the world’s largest clinical research organizations (CROs), providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 global professionals works in partnership with biopharmaceutical leaders, emerging innovators and sites to design and deliver clinical trials with patients in mind, increasing access and participation to make clinical research a care option for anyone, anywhere. Our depth of industry knowledge and strong track record gained over the past 40 years is moving the industry forward and advancing clinical research in healthcare’s most complex areas, while our innovation ecosystem offers the best solutions to make every phase of the clinical trial process more efficient. With the people, insight and focus on operational excellence, we work With HeartTM every day to treat patients with dignity and continuously learn from their experiences, so every trial makes a difference. For more information, visit parexel.com and follow us on LinkedIn, Twitter, Facebook and Instagram.
MEDIA
Lori Preuit Dorer
+1 513 496 8121
Lori.Dorer@parexel.com
Danaka Williams
+1 984 298 4207
Danaka.Williams@parexel.com
![](https://ml.globenewswire.com/media/NzY3OGE1YjQtZmJkMC00MzQ1LTk5MWMtM2M2NzY4YmQ0OWFmLTEwMjAxNjk=/tiny/Parexel-International-LLC.png)
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.